Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

Inclusion Criteria: * CHC GT1 infection for at least 6 months with with HCV-RNA ≥10,000 IU/mL. * Treatment naive, non-cirrhotic participants will be eligible for inclusion in Study Part A * Non-cirrhotic subjects who failed previous (peg)interferon/ribavirin treatment for CHC and cirrhotics, whether treatment naive or treatment failure, will be eligible for inclusion in Study Part B * To participate in Study Part C, participants must have completed the required post-treatment follow-up in Study Part A or Part B * Weight ≥ 10 kg to ≤ 125 kg * Body surface area (BSA) ≥0.46 m\^2 and ≤2.5 m\^2 * Previous liver biopsy with histology consistent with chronic hepatitis C and no other etiology within 2 years of the screening visit * Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the screening visit or between the screening visit and Day 1 with no findings suspicious for hepatocellular carcinoma * Participant must be able to adhere to dose and visit schedules Exclusion Criteria: * Known co-infection with the the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive) * For Study Part A, participant received any prior hepatitis C treatment, including herbal remedies, with known hepatotoxicity * For Study Part B, participant received treatment with ribavirin within 90 days or any interferon alpha within 30 days prior to screening * For Study Part B, participant received previous treatment with a hepatitis C virus protease inhibitor (excepting participants in study P07614, Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1) * For Study Part B, participant required discontinuation of previous (peg)interferon/ribavirin therapy for an adverse event considered by the investigator to be related to (peg)interferon and/or ribavirin * For Study Part B, participant is currently taking any antiviral/immunomodulatory treatment for hepatitis C * Participant has taken any investigational drugs, except boceprevir * Participant has received any of the following medication(s) within 2 weeks prior to the Day 1 visit: midazolam, pimozide, amiodarone, flecainide, propafenone, quinidine, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine) * Participation in any other clinical trial within 30 days of enrollment or intent to participate in another clinical trial during participation in the current study * Evidence of decompensated liver disease * Child Pugh score \>6 (class B and C) * History of diabetes or hypertension or was born prior to 32 weeks of gestation and has clinically significant ocular examination findings * Pre-existing clinically significant psychiatric condition(s) * Clinical diagnosis of substance abuse * Any pre-existing medical condition that could interfere with participation in and completion of the study * Evidence of active or suspected malignancy * Females who are pregnant, nursing, or intend to become pregnant during the study period * Allergy or sensitivity to the investigational products or excipients